This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Multiple Sclerosis/ Demyelinating Disease  • Dermatology  • Immunotherapy  • Immunologic Disorders  • Immunology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Neurol. 2002;59:726-731.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

DEMYELINATION IS the partial or total loss of the myelin sheath of nerve fibers following normal myelin development. Multiple sclerosis (MS) is the most common acquired inflammatory demyelinating disease of the central nervous system. The presumed immune-mediated nature of demyelinating diseases prompted evaluation of immunomodulatory and immunosuppressive agents for their treatment. The management of demyelinating diseases, in particular MS, has evolved significantly during the last decade. This has shifted the emphasis from treatment of acute relapses and management of symptoms to pharmacotherapy aimed at altering the natural history of the disease. Current relapse therapy, with glucocorticoids, had its origin in the 1950s and is used to accelerate recovery with no clear impact on the degree of improvement from acute neurologic dysfunction. For more than 100 years, symptom management has used unapproved or off-label uses of agents, with their expected benefit based on anecdotal reports or small case series. These interventions, . . . [Full Text of this Article]

TREATMENT OF CLINICALLY ISOLATED SYNDROMES


TREATMENT OF RR MS

TREATMENT OF SP MS

TREATMENT OF PRIMARY PROGRESSIVE MS

TREATMENT OF PROGRESSIVE RELAPSING MS

TREATMENT OF OTHER DEMYELINATING DISEASES

CONCLUSIONS


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Long-term daclizumab therapy in relapsing-remitting multiple sclerosis
Rojas et al.
Therapeutic Advances in Neurological Disorders 2009;2:291-297.
ABSTRACT  

Primary progressive multiple sclerosis: cerebrospinal fluid considerations
Freedman
Mult Scler 2004;10:S31-S35.
ABSTRACT  

Primary progressive multiple sclerosis: cerebrospinal fluid considerations
Freedman
Mult Scler 2004;10:S31-S35.
ABSTRACT